Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada (GRACE)
Real-World Experience of Elagolix For the Treatment of Endometriosis in Canada: An Observational Cohort Study (GRACE)
Sponsor: AbbVie
A observational or N/A phase clinical study on Endometriosis, this trial is completed. The trial is conducted by AbbVie and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2022 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Sep 2022 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
-
Apr 2021 — Oct 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
-
Jan 2020 — Oct 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Gatineau, Canada , Greater Sudbury, Canada , Halifax, Canada , Hamilton, Canada , LaSalle, Canada , London, Canada , Longueuil, Canada , Montreal, Canada and 5 more locations